Bio-Rad Laboratories (BIO) Cash from Investing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash from Investing Activities for 18 consecutive years, with -$66.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 42.2% year-over-year to -$66.7 million in Q2 2026; TTM through Jun 2026 was -$237.1 million, a 19.33% decrease from a year earlier, with the FY2025 full-year figure at -$189.7 million, down 18.41% from the prior year.
• Cash from Investing Activities was -$66.7 million for Q2 2026 at Bio-Rad Laboratories, up from -$93.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $72.2 million in Q4 2023 and troughed at -$916.1 million in Q1 2022.
• A 5-year average of -$94.3 million and a median of -$49.4 million in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 223.28% in 2023 and tumbled 3313.79% in 2026, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$58.6 million in 2022, then jumped by 223.28% to $72.2 million in 2023, then tumbled by 142.25% to -$30.5 million in 2024, then fell by 12.13% to -$34.2 million in 2025, then tumbled by 95.03% to -$66.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$66.7 million (Q2 2026), -$93.2 million (Q1 2026), and -$34.2 million (Q4 2025), per Business Quant data.